Baseline demographics and clinical characteristics of patients with ulcerative colitis.
| Demographic or characteristic . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . | P value . |
|---|---|---|---|---|
| Age, years, mean (SD) | 41.5 (13.40) | 40.9 (14.06) | 42.8 (13.33) | .0709 |
| Age range, years, n (%) | ||||
| 18–34 | 260 (34.8) | 252 (36.6) | 132 (31.4) | .2961 |
| 35–49 | 246 (32.9) | 210 (30.5) | 140 (33.3) | |
| 50–64 | 233 (31.1) | 214 (31.1) | 137 (32.5) | |
| ≥65 | 9 (1.2) | 12 (1.7) | 12 (2.9) | |
| Sex, n (%) | ||||
| Male | 408 (54.5) | 370 (53.8) | 220 (52.3) | .7527 |
| Female | 340 (45.5) | 318 (46.2) | 201 (47.7) | |
| US region, n (%) | ||||
| Northeast | 147 (19.7) | 132 (19.2) | 66 (15.7) | .0308 |
| North Central | 150 (20.1) | 186 (27.0) | 97 (23.0) | |
| South | 357 (47.7) | 274 (39.8) | 195 (46.3) | |
| West | 92 (12.3) | 94 (13.7) | 61 (14.5) | |
| Other or unknown | 2 (0.3) | 2 (0.3) | 2 (0.5) | |
| All-cause hospitalizations, n (%) | ||||
| 0 | 620 (82.9) | 483 (70.2) | 372 (88.4) | <.0001 |
| 1 | 102 (13.6) | 149 (21.7) | 41 (9.7) | |
| >1 | 26 (3.5) | 56 (8.1) | 8 (1.9) | |
| IBD-related hospitalizations, n (%) | ||||
| 0 | 632 (84.5) | 491 (71.4) | 377 (89.5) | <.0001 |
| 1 | 96 (12.8) | 146 (21.2) | 37 (8.8) | |
| >1 | 20 (2.7) | 51 (7.4) | 7 (1.7) | |
| Comorbidities | ||||
| Cardiovascular disease | 8 (1.1) | 9 (1.3) | 1 (0.2) | .1969 |
| Chronic pulmonary disease | 61 (8.2) | 49 (7.1) | 29 (6.9) | .6596 |
| Renal disease | 10 (1.3) | 8 (1.2) | 6 (1.4) | .9229 |
| Liver disease | 34 (4.5) | 36 (5.2) | 23 (5.5) | .7435 |
| Cancer | 11 (1.5) | 10 (1.5) | 17 (4.0) | .0046 |
| Diabetes mellitus | 45 (6.0) | 44 (6.4) | 23 (5.5) | .8183 |
| Rheumatic diseasea | 5 (0.7) | 7 (1.0) | 3 (0.7) | .7385 |
| Anemia | 85 (11.4) | 134 (19.5) | 53 (12.6) | < .0001 |
| Mental disordersb | 2 (0.3) | 4 (0.6) | 3 (0.7) | .4727 |
| ACCI score, mean (SD) | 1.3 (1.50) | 1.3 (1.61) | 1.5 (1.67) | .1078 |
| Immunomodulators, immunosuppressive agents, or anti-inflammatory agents, n (%) | ||||
| 1–60 days covered | 63 (8.4) | 91 (13.2) | 41 (9.7) | <.0001 |
| >60 days covered | 685 (91.6) | 548 (79.7) | 345 (81.9) | |
| No claims | 0 (0.0) | 49 (7.1) | 35 (8.3) | |
| Infections, n (%) | 66 (8.8) | 59 (8.6) | 33 (7.8) | .8428 |
| Surgery (UC related),cn (%) | 0 (0.0) | 2 (0.3) | 2 (0.5) | .1258 |
| Disease extent,dn (%) | ||||
| Pancolitis | 214 (28.6) | 246 (35.8) | 146 (34.7) | .0093 |
| Left-sided | 56 (7.5) | 42 (6.1) | 45 (10.7) | .0202 |
| Proctosigmoiditis | 42 (5.6) | 36 (5.2) | 24 (5.7) | .9294 |
| Proctitis | 34 (4.5) | 28 (4.1) | 12 (2.9) | .3599 |
| Other or unspecified | 402 (53.7) | 336 (48.8) | 194 (46.1) | .0284 |
| Demographic or characteristic . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . | P value . |
|---|---|---|---|---|
| Age, years, mean (SD) | 41.5 (13.40) | 40.9 (14.06) | 42.8 (13.33) | .0709 |
| Age range, years, n (%) | ||||
| 18–34 | 260 (34.8) | 252 (36.6) | 132 (31.4) | .2961 |
| 35–49 | 246 (32.9) | 210 (30.5) | 140 (33.3) | |
| 50–64 | 233 (31.1) | 214 (31.1) | 137 (32.5) | |
| ≥65 | 9 (1.2) | 12 (1.7) | 12 (2.9) | |
| Sex, n (%) | ||||
| Male | 408 (54.5) | 370 (53.8) | 220 (52.3) | .7527 |
| Female | 340 (45.5) | 318 (46.2) | 201 (47.7) | |
| US region, n (%) | ||||
| Northeast | 147 (19.7) | 132 (19.2) | 66 (15.7) | .0308 |
| North Central | 150 (20.1) | 186 (27.0) | 97 (23.0) | |
| South | 357 (47.7) | 274 (39.8) | 195 (46.3) | |
| West | 92 (12.3) | 94 (13.7) | 61 (14.5) | |
| Other or unknown | 2 (0.3) | 2 (0.3) | 2 (0.5) | |
| All-cause hospitalizations, n (%) | ||||
| 0 | 620 (82.9) | 483 (70.2) | 372 (88.4) | <.0001 |
| 1 | 102 (13.6) | 149 (21.7) | 41 (9.7) | |
| >1 | 26 (3.5) | 56 (8.1) | 8 (1.9) | |
| IBD-related hospitalizations, n (%) | ||||
| 0 | 632 (84.5) | 491 (71.4) | 377 (89.5) | <.0001 |
| 1 | 96 (12.8) | 146 (21.2) | 37 (8.8) | |
| >1 | 20 (2.7) | 51 (7.4) | 7 (1.7) | |
| Comorbidities | ||||
| Cardiovascular disease | 8 (1.1) | 9 (1.3) | 1 (0.2) | .1969 |
| Chronic pulmonary disease | 61 (8.2) | 49 (7.1) | 29 (6.9) | .6596 |
| Renal disease | 10 (1.3) | 8 (1.2) | 6 (1.4) | .9229 |
| Liver disease | 34 (4.5) | 36 (5.2) | 23 (5.5) | .7435 |
| Cancer | 11 (1.5) | 10 (1.5) | 17 (4.0) | .0046 |
| Diabetes mellitus | 45 (6.0) | 44 (6.4) | 23 (5.5) | .8183 |
| Rheumatic diseasea | 5 (0.7) | 7 (1.0) | 3 (0.7) | .7385 |
| Anemia | 85 (11.4) | 134 (19.5) | 53 (12.6) | < .0001 |
| Mental disordersb | 2 (0.3) | 4 (0.6) | 3 (0.7) | .4727 |
| ACCI score, mean (SD) | 1.3 (1.50) | 1.3 (1.61) | 1.5 (1.67) | .1078 |
| Immunomodulators, immunosuppressive agents, or anti-inflammatory agents, n (%) | ||||
| 1–60 days covered | 63 (8.4) | 91 (13.2) | 41 (9.7) | <.0001 |
| >60 days covered | 685 (91.6) | 548 (79.7) | 345 (81.9) | |
| No claims | 0 (0.0) | 49 (7.1) | 35 (8.3) | |
| Infections, n (%) | 66 (8.8) | 59 (8.6) | 33 (7.8) | .8428 |
| Surgery (UC related),cn (%) | 0 (0.0) | 2 (0.3) | 2 (0.5) | .1258 |
| Disease extent,dn (%) | ||||
| Pancolitis | 214 (28.6) | 246 (35.8) | 146 (34.7) | .0093 |
| Left-sided | 56 (7.5) | 42 (6.1) | 45 (10.7) | .0202 |
| Proctosigmoiditis | 42 (5.6) | 36 (5.2) | 24 (5.7) | .9294 |
| Proctitis | 34 (4.5) | 28 (4.1) | 12 (2.9) | .3599 |
| Other or unspecified | 402 (53.7) | 336 (48.8) | 194 (46.1) | .0284 |
Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; IBD, inflammatory bowel disease; SD, standard deviation; UC, ulcerative colitis.
aPatients with diagnosis codes for rheumatic disease who were not included in rheumatoid arthritis exclusion criterion.
bIncluding depression and anxiety.
cIn total, 2 patients had undergone total colectomy.
dDisease extent was classified according to the following hierarchy: pancolitis, left-sided, proctosigmoiditis, proctitis, and other/unspecified.
Baseline demographics and clinical characteristics of patients with ulcerative colitis.
| Demographic or characteristic . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . | P value . |
|---|---|---|---|---|
| Age, years, mean (SD) | 41.5 (13.40) | 40.9 (14.06) | 42.8 (13.33) | .0709 |
| Age range, years, n (%) | ||||
| 18–34 | 260 (34.8) | 252 (36.6) | 132 (31.4) | .2961 |
| 35–49 | 246 (32.9) | 210 (30.5) | 140 (33.3) | |
| 50–64 | 233 (31.1) | 214 (31.1) | 137 (32.5) | |
| ≥65 | 9 (1.2) | 12 (1.7) | 12 (2.9) | |
| Sex, n (%) | ||||
| Male | 408 (54.5) | 370 (53.8) | 220 (52.3) | .7527 |
| Female | 340 (45.5) | 318 (46.2) | 201 (47.7) | |
| US region, n (%) | ||||
| Northeast | 147 (19.7) | 132 (19.2) | 66 (15.7) | .0308 |
| North Central | 150 (20.1) | 186 (27.0) | 97 (23.0) | |
| South | 357 (47.7) | 274 (39.8) | 195 (46.3) | |
| West | 92 (12.3) | 94 (13.7) | 61 (14.5) | |
| Other or unknown | 2 (0.3) | 2 (0.3) | 2 (0.5) | |
| All-cause hospitalizations, n (%) | ||||
| 0 | 620 (82.9) | 483 (70.2) | 372 (88.4) | <.0001 |
| 1 | 102 (13.6) | 149 (21.7) | 41 (9.7) | |
| >1 | 26 (3.5) | 56 (8.1) | 8 (1.9) | |
| IBD-related hospitalizations, n (%) | ||||
| 0 | 632 (84.5) | 491 (71.4) | 377 (89.5) | <.0001 |
| 1 | 96 (12.8) | 146 (21.2) | 37 (8.8) | |
| >1 | 20 (2.7) | 51 (7.4) | 7 (1.7) | |
| Comorbidities | ||||
| Cardiovascular disease | 8 (1.1) | 9 (1.3) | 1 (0.2) | .1969 |
| Chronic pulmonary disease | 61 (8.2) | 49 (7.1) | 29 (6.9) | .6596 |
| Renal disease | 10 (1.3) | 8 (1.2) | 6 (1.4) | .9229 |
| Liver disease | 34 (4.5) | 36 (5.2) | 23 (5.5) | .7435 |
| Cancer | 11 (1.5) | 10 (1.5) | 17 (4.0) | .0046 |
| Diabetes mellitus | 45 (6.0) | 44 (6.4) | 23 (5.5) | .8183 |
| Rheumatic diseasea | 5 (0.7) | 7 (1.0) | 3 (0.7) | .7385 |
| Anemia | 85 (11.4) | 134 (19.5) | 53 (12.6) | < .0001 |
| Mental disordersb | 2 (0.3) | 4 (0.6) | 3 (0.7) | .4727 |
| ACCI score, mean (SD) | 1.3 (1.50) | 1.3 (1.61) | 1.5 (1.67) | .1078 |
| Immunomodulators, immunosuppressive agents, or anti-inflammatory agents, n (%) | ||||
| 1–60 days covered | 63 (8.4) | 91 (13.2) | 41 (9.7) | <.0001 |
| >60 days covered | 685 (91.6) | 548 (79.7) | 345 (81.9) | |
| No claims | 0 (0.0) | 49 (7.1) | 35 (8.3) | |
| Infections, n (%) | 66 (8.8) | 59 (8.6) | 33 (7.8) | .8428 |
| Surgery (UC related),cn (%) | 0 (0.0) | 2 (0.3) | 2 (0.5) | .1258 |
| Disease extent,dn (%) | ||||
| Pancolitis | 214 (28.6) | 246 (35.8) | 146 (34.7) | .0093 |
| Left-sided | 56 (7.5) | 42 (6.1) | 45 (10.7) | .0202 |
| Proctosigmoiditis | 42 (5.6) | 36 (5.2) | 24 (5.7) | .9294 |
| Proctitis | 34 (4.5) | 28 (4.1) | 12 (2.9) | .3599 |
| Other or unspecified | 402 (53.7) | 336 (48.8) | 194 (46.1) | .0284 |
| Demographic or characteristic . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . | P value . |
|---|---|---|---|---|
| Age, years, mean (SD) | 41.5 (13.40) | 40.9 (14.06) | 42.8 (13.33) | .0709 |
| Age range, years, n (%) | ||||
| 18–34 | 260 (34.8) | 252 (36.6) | 132 (31.4) | .2961 |
| 35–49 | 246 (32.9) | 210 (30.5) | 140 (33.3) | |
| 50–64 | 233 (31.1) | 214 (31.1) | 137 (32.5) | |
| ≥65 | 9 (1.2) | 12 (1.7) | 12 (2.9) | |
| Sex, n (%) | ||||
| Male | 408 (54.5) | 370 (53.8) | 220 (52.3) | .7527 |
| Female | 340 (45.5) | 318 (46.2) | 201 (47.7) | |
| US region, n (%) | ||||
| Northeast | 147 (19.7) | 132 (19.2) | 66 (15.7) | .0308 |
| North Central | 150 (20.1) | 186 (27.0) | 97 (23.0) | |
| South | 357 (47.7) | 274 (39.8) | 195 (46.3) | |
| West | 92 (12.3) | 94 (13.7) | 61 (14.5) | |
| Other or unknown | 2 (0.3) | 2 (0.3) | 2 (0.5) | |
| All-cause hospitalizations, n (%) | ||||
| 0 | 620 (82.9) | 483 (70.2) | 372 (88.4) | <.0001 |
| 1 | 102 (13.6) | 149 (21.7) | 41 (9.7) | |
| >1 | 26 (3.5) | 56 (8.1) | 8 (1.9) | |
| IBD-related hospitalizations, n (%) | ||||
| 0 | 632 (84.5) | 491 (71.4) | 377 (89.5) | <.0001 |
| 1 | 96 (12.8) | 146 (21.2) | 37 (8.8) | |
| >1 | 20 (2.7) | 51 (7.4) | 7 (1.7) | |
| Comorbidities | ||||
| Cardiovascular disease | 8 (1.1) | 9 (1.3) | 1 (0.2) | .1969 |
| Chronic pulmonary disease | 61 (8.2) | 49 (7.1) | 29 (6.9) | .6596 |
| Renal disease | 10 (1.3) | 8 (1.2) | 6 (1.4) | .9229 |
| Liver disease | 34 (4.5) | 36 (5.2) | 23 (5.5) | .7435 |
| Cancer | 11 (1.5) | 10 (1.5) | 17 (4.0) | .0046 |
| Diabetes mellitus | 45 (6.0) | 44 (6.4) | 23 (5.5) | .8183 |
| Rheumatic diseasea | 5 (0.7) | 7 (1.0) | 3 (0.7) | .7385 |
| Anemia | 85 (11.4) | 134 (19.5) | 53 (12.6) | < .0001 |
| Mental disordersb | 2 (0.3) | 4 (0.6) | 3 (0.7) | .4727 |
| ACCI score, mean (SD) | 1.3 (1.50) | 1.3 (1.61) | 1.5 (1.67) | .1078 |
| Immunomodulators, immunosuppressive agents, or anti-inflammatory agents, n (%) | ||||
| 1–60 days covered | 63 (8.4) | 91 (13.2) | 41 (9.7) | <.0001 |
| >60 days covered | 685 (91.6) | 548 (79.7) | 345 (81.9) | |
| No claims | 0 (0.0) | 49 (7.1) | 35 (8.3) | |
| Infections, n (%) | 66 (8.8) | 59 (8.6) | 33 (7.8) | .8428 |
| Surgery (UC related),cn (%) | 0 (0.0) | 2 (0.3) | 2 (0.5) | .1258 |
| Disease extent,dn (%) | ||||
| Pancolitis | 214 (28.6) | 246 (35.8) | 146 (34.7) | .0093 |
| Left-sided | 56 (7.5) | 42 (6.1) | 45 (10.7) | .0202 |
| Proctosigmoiditis | 42 (5.6) | 36 (5.2) | 24 (5.7) | .9294 |
| Proctitis | 34 (4.5) | 28 (4.1) | 12 (2.9) | .3599 |
| Other or unspecified | 402 (53.7) | 336 (48.8) | 194 (46.1) | .0284 |
Abbreviations: ACCI, age-adjusted Charlson Comorbidity Index; IBD, inflammatory bowel disease; SD, standard deviation; UC, ulcerative colitis.
aPatients with diagnosis codes for rheumatic disease who were not included in rheumatoid arthritis exclusion criterion.
bIncluding depression and anxiety.
cIn total, 2 patients had undergone total colectomy.
dDisease extent was classified according to the following hierarchy: pancolitis, left-sided, proctosigmoiditis, proctitis, and other/unspecified.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
